中国医药: 第九届董事会第30次会议决议公告

Meeting Overview - The 30th meeting of the 9th Board of Directors of China National Pharmaceutical Group Co., Ltd. was held on August 8, 2025, combining in-person and communication methods, chaired by Chairman and General Manager Yang Guang [1] - All 7 directors attended the meeting, and the meeting complied with the relevant provisions of the Company Law and Articles of Association, making the resolutions valid [1] Resolutions Passed - The meeting approved the proposal to amend the Articles of Association, with a unanimous vote of 7 in favor [2] - The proposal to amend the Rules of Procedure for Shareholders' Meetings was also approved, with a unanimous vote of 7 in favor [2] - The proposal to amend the Rules of Procedure for Board Meetings received unanimous approval, with 7 votes in favor [2] - The proposal to amend the Independent Director System was approved unanimously, with 7 votes in favor [2] - The proposal to amend the External Guarantee Management System was approved unanimously, with 7 votes in favor [2] - The board agreed to nominate Ms. Sun Zhuo as a candidate for director, pending approval at the shareholders' meeting, with a unanimous vote of 7 in favor [3] Other Decisions - The board decided to waive the priority right to acquire a 5% limited partnership interest in the Life and Health Industry Fund, which corresponds to a subscribed capital of 100 million yuan and a paid-in capital of 40 million yuan, with the transfer price set at a minimum of 39.5805 million yuan [4][5] - The board approved the proposal to convene the sixth temporary shareholders' meeting of 2025, with a unanimous vote of 7 in favor [6]